利用常规收集的健康数据(英格兰)识别原发性乳腺癌患者后续疾病相关事件:乳腺癌临床试验中替代医院随访的实用选择
该研究利用英格兰常规收集的健康数据(含癌症登记和医院统计),与四项早期乳腺癌临床试验的前瞻性复发数据链接,开发并测试识别复发事件的流程。结果显示该流程识别复发的特异性高(97.9-99.9%),敏感性和阳性预测值有变异,但基于常规数据与试验数据计算的生存结局相似。
要点
- 常规收集健康数据识别乳腺癌复发的特异性为97.9-99.9%,阴性预测值为95.2-99.6%。
- 敏感性和阳性预测值变异较大:敏感性72.9-97.2%,阳性预测值82.6-99.5%。
- 常规数据与试验数据计算的至复发时间、无病生存和总生存估计相似。
核心结论
- 在主要分析完成后,使用常规收集的健康数据替代医院数据收集来识别癌症复发是可能的,且具有合理的准确性。
研究设计与样本
- 链接四项早期乳腺癌临床试验(TACT2、POETIC、IMPORT-HIGH、FAST-Forward)的前瞻性复发数据(金标准)与NHS England管理的常规收集健康数据(包括癌症登记和医院统计)。
主要发现
- 最终流程使用癌症登记诊断识别初始乳腺癌以进行质量控制,并识别第二原发癌;通过死亡日期和死因识别死亡;主要通过转移的直接指标(如ICD10编码C77X-79X)识别远处复发;通过相关手术的OPCS4编码识别局部复发。
- 对于至复发时间、无病生存和总生存,研究事件与常规数据事件之间的一致性合理。
- 三个训练数据集合并后,所有终点的特异性良好(范围97.9-99.9%),阴性预测值也良好(范围95.2-99.6%);敏感性和阳性预测值变异较大,敏感性范围72.9-97.2%,阳性预测值范围82.6-99.5%。
- 在测试数据集中考虑时,数值相似。
- 至复发时间、无病生存和总生存的生存估计在研究数据与常规数据之间相似。
关键数值与推荐
- 远处复发主要通过转移的直接指标(如ICD10编码C77X-79X)识别。
- 局部复发通过相关手术的OPCS4编码识别。
- 死亡通过死亡日期和死因识别。
- 第二原发癌和初始乳腺癌质控通过癌症登记诊断识别。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With continued improvements in breast cancer (BC) outcomes and risk of recurrence occurring until at least 20 years post-diagnosis, it is important to continue to follow up clinical trial participants to characterise long-term treatment impact. Traditionally, follow-up has been via hospitals, entailing burden on patients and site staff. Using routinely collected health datasets (RCHD) as an alternative method is attractive, but historically, cancer recurrence is poorly recorded, unlike initial cancer diagnosis. Here we use data collected prospectively from large, multi-centre BC clinical trials to develop and test a procedure to identify recurrence within RCHD. METHODS: Data from four trials of early breast cancer (TACT2, POETIC, IMPORT-HIGH and FAST-Forward) where recurrence data has been collected prospectively (gold standard) was linked with RCHD (incl. cancer registry and hospital episode statistics; HES) managed by NHS England. The procedure identified episodes of clinical activity within RCHD to classify each event type (local and distant recurrence, second cancers, death) separately, then combined to derive time-to-recurrence (TTR), disease-free survival (iDFS) and overall survival (OS) outcomes. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated. Hazard ratios using Cox regression modelling, log-rank test p-values, and 3-year survival rates for the randomised treatments were reported separately for RCHD and trial data. RESULTS: The final procedure used Cancer Registry diagnoses to identify initial BCs for quality control purposes and second primary cancers. Deaths were identified via death dates and cause. Distant recurrence was identified predominantly by direct indicators of metastases (e.g. ICD10 codes C77X-79X). Local recurrence was identified via relevant surgeries' OPCS4 codes. For TTR, iDFS and OS, agreement between study and RCHD events was reasonable. Specificity was good across all endpoints (range: 97.9-99.9% for three training datasets combined), as was NPV (range: 95.2-99.6%). Sensitivity and PPV were more variable, with sensitivity ranging between 72.9 and 97.2% and PPV ranging between 82.6 and 99.5%. Values were similar when considering the test dataset. Survival estimates for TTR, iDFS and OS were similar between study and RCHD data. CONCLUSION: It is possible, with reasonable accuracy, to identify cancer recurrences using RCHD in the place of hospital-based data collection after the point of primary analysis.
引用
- Kilburn LS, Hinder V, Mahati SG, et al. Use of routinely collected health data (England) to identify subsequent disease-related events in patients with primary breast cancer: a practical alternative to hospital-based follow-up for breast cancer clinical trials. Trials. 2025. PMID: 41013616. doi:10.1186/s13063-025-09085-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。